Preferred Label : Allogeneic Anti-BCMA CAR T Cells P-BCMA-ALLO1;
NCIt synonyms : Allogeneic Tscm-rich Anti-BCMA CAR T Cells P-BCMA-ALLO1; Allogeneic Anti-BCMA-CAR-expressing Tscm P-BCMA-ALLO1;
NCIt definition : An off-the-shelf (OTS) preparation composed of human allogeneic T-cells and containing
primarily stem cell memory T-cells (Tscm) that are transfected by electroporation
with a proprietary transposon-based DNA plasmid vector (PiggyBac; PB) encoding for
an undisclosed drug selection gene encoding for a selectable marker to generate close
to 100% CAR-based product, a caspase-based safety switch to reduce or eliminate the
product in vivo if needed, and a B-cell maturation antigen (BCMA; tumor necrosis factor
receptor superfamily member 17; TNFRSF17)-specific single domain variable heavy chain
(VH) chimeric antigen receptor (CAR) (VCAR), with potential immunostimulating and
antineoplastic activities. The CAR T-cells are also site specifically gene-edited
with Cas-CLOVER (CC) to eliminate surface expression of both T-cell receptor (TCR)
and beta-2 microglobulin (beta 2M) to decrease major histocompatibility complex (MHC)
class I expression and further selected, by depletion of residual CD3-positive/TCR-positive
cells, and expanded to yield Tscm enriched allogeneic transposed CAR-T cells. Upon
administration, allogeneic anti-BCMA CAR T cells P-BCMA-ALLO1 specifically recognize
and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a tumor-specific
antigen and a member of the tumor necrosis factor receptor superfamily (TNFRSF) that
binds to both a proliferation-inducing ligand (APRIL; TNFSF13) and B-cell activating
factor (BAFF; TNFSF13B), plays a key role in plasma cell survival. BCMA is found on
the surfaces of plasma cells and is overexpressed on malignant plasma cells.;
Molecule name : P-BCMA-ALLO-1; P-BCMA-ALLO 1;
NCI Metathesaurus CUI : CL1664652;
Origin ID : C181747;
UMLS CUI : C5557242;
Semantic type(s)
- Cell [UMLS semantic type]
- concept_is_in_subset
- has_target
